Amphastar Pharmaceuticals (AMPH) Retained Earnings (2013 - 2026)

Amphastar Pharmaceuticals has reported Retained Earnings for 14 years, with the latest figure at $703.6 million in Q2 2026.

• On a quarterly basis, Retained Earnings rose 12.57% year-over-year to $703.6 million in Q2 2026; TTM through Jun 2026 was $703.6 million, a 12.57% increase from a year earlier, with the FY2025 full-year figure at $666.9 million, up 17.25% from the prior year.
• Retained Earnings was $703.6 million for Q2 2026 at Amphastar Pharmaceuticals, up from $673.3 million in the prior quarter.
• The five-year high for Retained Earnings was $703.6 million in Q2 2026, with the low at $433.5 million in Q1 2022.
• Average Retained Earnings over 5 years is $535.8 million, with a median of $488.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings advanced 3.68% in 2022, then increased 27.47% in 2025.
• Over 5 years, Retained Earnings stood at $455.1 million in 2022, then grew by 6.81% to $486.1 million in 2023, then grew by 17.02% to $568.8 million in 2024, then advanced by 17.25% to $666.9 million in 2025, then grew by 5.51% to $703.6 million in 2026.
• The last three Retained Earnings figures came in at $703.6 million (Q2 2026), $673.3 million (Q1 2026), and $666.9 million (Q4 2025), per Business Quant data.